ASX:PMEPro Medicus Stock Price, Forecast & News

A$26.98

+0.68 (+2.59 %)

(As of 05/13/2020)

Add

Compare

Today's Range

A$25.82

Now: A$26.98▼

A$27.12

50-Day Range

A$22.44

MA: A$25.61▼

A$27.28

52-Week Range

A$14.50

Now: A$26.98▼

A$38.39

Volume285,954 shs

Average VolumeN/A

Market Capitalization$2.80 billion

P/E Ratio127.87

Dividend Yield0.35%

BetaN/A

Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions worldwide. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Pro Medicus.

2.6 Community Rank

Outperform Votes
Pro Medicus has received 21 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Pro Medicus has received 19 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Pro Medicus has received 52.50% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Pro Medicus and other stocks. Vote “Outperform” if you believe PME will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PME will underperform the S&P 500 over the long term. You may vote once every thirty days.

2.5 Dividend Strength

Dividend Leadership
Pro Medicus is a leading dividend payer. It pays a dividend yield of 0.35%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Pro Medicus does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Pro Medicus is 47.39 %. This payout ratio is at a healthy, sustainable level, below 75%.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pro Medicus insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$203,512.00 in company stock and sold A$0.00 in company stock.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Pro Medicus are expected to decrease by -100.00% in the coming year, from A$0.13 to A$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pro Medicus is 127.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pro Medicus is 127.87, which means that it is trading at a more expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 35.61.
Price to Book Value per Share Ratio
Pro Medicus has a P/B Ratio of 53.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.62 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX

Industry Health Information Services

Sub-IndustryN/A

SectorComputer and Technology

Current SymbolASX:PME

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.promed.com.au

Phone61 3 9429 8800

Debt

Debt-to-Equity Ratio4.88

Current Ratio4.41

Quick Ratio4.34

Price-To-Earnings

Trailing P/E Ratio127.87

Forward P/E Ratio200.36

P/E GrowthN/A

Sales & Book Value

Annual Sales$54.08 million

Price / Sales51.86

Cash FlowA$0.38 per share

Price / Cash Flow71.76

Book ValueA$0.50 per share

Price / Book53.53

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares103,947,000

Market Cap$2.80 billion

Next Earnings DateN/A

OptionableNot Optionable

Receive PME News and Ratings via Email

Sign-up to receive the latest news and ratings for PME and its competitors with MarketBeat's FREE daily newsletter.

Pro Medicus (ASX:PME) Frequently Asked Questions

How has Pro Medicus' stock been impacted by COVID-19 (Coronavirus)?

Pro Medicus' stock was trading at A$16.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PME stock has increased by 62.0% and is now trading at A$26.98. View which stocks have been most impacted by Coronavirus.

How often does Pro Medicus pay dividends? What is the dividend yield for Pro Medicus?

Pro Medicus announced a Interim dividend on Friday, February 14th. Investors of record on Friday, March 20th will be paid a dividend of 0.06 per share on Friday, March 20th. This represents a dividend yield of 0.24%. The ex-dividend date is Thursday, March 5th. This is a positive change from Pro Medicus's previous Interim dividend of A$0.04. View Pro Medicus' dividend history.

Has Pro Medicus been receiving favorable news coverage?

News coverage about PME stock has been trending very negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pro Medicus earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutPro Medicus.

Who are some of Pro Medicus' key competitors?

Some companies that are related to Pro Medicus include 10x Genomics (TXG), Schrodinger (SDGR), Compugroup Medical (COP), Craneware (CRW), Alcidion Group (ALC), Kneat.com (KSI), Medadvisor (MDR), Resapp Health (RAP), Mach7 Technologies (M7T), CogState (CGS), Sensyne Health (SENS), Reliq Health Technologies (RHT), Novita Healthcare (NHL), Vitalhub (VHI) and Induction Healthcare Group (INHC). View all competitors.

What other stocks do shareholders of Pro Medicus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pro Medicus investors own include ImmuPharma (IMM), Blackmores (BKL), Bank of America (BAC), Boeing (BA), Accent Group (AX1), Axos Financial (AX), ARB (ARB), Appen (APX), Arista Networks (ANET) and Altium (ALU).

Who are Pro Medicus' key executives?

Pro Medicus' management team includes the following people:

Dr. Sam Aaron Hupert, Co-Founder, Deputy Chairman, CEO & MD
Mr. Anthony Barry Hall, Co-Founder, Technology Director & Exec. Director
Dr. Malte Westerhoff, Global Chief Technology Officer
Mr. Brad Levin, GM of North America & Global Head of Marketing
Mr. Danny Tauber, Gen. Mang. of Australia

What is Pro Medicus' stock symbol?

Pro Medicus trades on the ASX under the ticker symbol "PME."

What is Pro Medicus' stock price today?

One share of PME stock can currently be purchased for approximately A$26.98.

How big of a company is Pro Medicus?

Pro Medicus has a market capitalization of $2.80 billion and generates $54.08 million in revenue each year.

What is Pro Medicus' official website?

The official website for Pro Medicus is www.promed.com.au.

How can I contact Pro Medicus?

The company can be reached via phone at 61 3 9429 8800.

This page was last updated on 5/31/2020 by MarketBeat.com Staff